Nexalin CEO details clinical progress, Gen-3 HALO headset, and government market expansion

Nexalin Technology, Inc.

Positive clinical results from UCSD study: Gen-2 tACS reduced post-concussive and PTSD symptoms in veterans with mTBI.
Published insomnia study showed statistically significant sleep improvements vs placebo; 6 additional peer-reviewed studies on 15mA waveform.
New Gen-3 HALO Clarity headset with DIFS technology enables at-home treatment under Virtual Clinic remote physician monitoring; ahead of schedule.
Formed military and government advisory board led by former Deputy Assistant Secretary of Defense; targeting DoD, VA, HHS markets.
Received regulatory approval in Oman with sales to new Mental Health Center; patents extended through 2040 with four key patents and three pending.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.